BrightSpring Health Services, Inc. (BTSG): what the price assumes

In the published model solve dated 2026-Q2, anchored at $60.64, BrightSpring Health Services, Inc. (BTSG) is priced for today's economics sustained for ~7.5 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/BTSG

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.9% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: n/a

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Pharmacy Solutions is 89% of revenue, and most of each revenue dollar is drug cost moving through the business, which leaves an operating margin of 2.4% and makes margin, not growth, the number that decides the outcome.
• Government programmes are the single largest exposure: the 10-K says the company "derive[s] substantial revenue from government healthcare programs, primarily Medicare and Medicaid", and on a 2.4% margin a modest rate change is a large profit change.
• Second-quarter results land on 31 July 2026, measured against full-year revenue guidance the company raised on 1 May to a range of $14.73 billion to $15.23 billion.

Bull Case

One number decides this investment, and it is 2.4%. That is the share of each revenue dollar BrightSpring keeps as operating profit. On $13.65 billion of revenue that is a business whose income statement is mostly pharmaceutical cost passing from a wholesaler to a patient. The arithmetic runs generously in one direction, though: lift that 2.4% by a single percentage point and operating profit rises by close to half again, without selling one additional prescription.

There is evidence the lift is happening rather than being hoped for. The annual filing attributes the year's profit growth to revenue rising with "selling, general, and administrative expenses growing less than the volume growth rate and demonstrating economies of scale". That is the whole thesis in one clause. A distribution-shaped business earns its return by adding volume to a fixed cost base, and the fixed cost base here covers pharmacy licensure, payor contracting, compliance infrastructure and a national logistics network that a smaller competitor has to build from scratch.

The scale itself is the moat, and management describes it as diversification rather than dominance: "Our scale provides complementary diversification and risk mitigation in payor sources, end markets, and geographies, while also creating exposure and access to a broader set of market growth opportunities." The Pharmacy Solutions segment runs "long-term institutional pharmacies, hospice pharmacies, specialty oncology pharmacies, and home infusion centers", four channels that sell into overlapping referral relationships. A hospice referral becomes a hospice pharmacy patient; a discharge becomes a home infusion patient. The customer acquisition cost of the second service is close to zero once the first exists.

Growth against the comparison set is not close. Revenue has been compounding near 28%, against ENSG at 19.2%, PACS at 22.2%, ADUS at 19.6%, AVAH at 20.5% and OPCH at 9.3%. BrightSpring is simultaneously the largest company in that group by revenue and the fastest growing, which is an unusual pair.

Execution has matched it so far. Management has raised guidance on nine separate occasions and set new guidance twice since 2024, a cadence that is either genuine conservatism in the initial number or genuine outperformance against it, and either reading favours the holder. First-quarter revenue was $3.61 billion, and the full-year outlook went up with it.

The portfolio has also been simplified rather than sprawled. The Community Living business went to Sevita for $835 million in cash, finalised in March 2026 after the FTC required the buyer to shed 126 intermediate care facilities. What remains is a pharmacy business with a home and community care business attached, and the pharmacy business is the one compounding.

Bear Case

Omnicare is a division of CVS Health. The 10-K names it directly as a nationwide competitor, and that single ownership fact frames the whole competitive problem: BrightSpring competes for institutional pharmacy volume against a business sitting inside an insurer, a pharmacy benefit manager and a retail chain. The filing is candid that "some of our competitors have vertically integrated business models with commercial" insurers, and that the owners of skilled nursing facilities are themselves "entering the facility-based pharmacy market, particularly in areas of their geographic concentration". A customer that becomes a competitor is a different kind of threat from a competitor that becomes larger.

In home infusion, the comparison is more direct. OPCH runs $5.67 billion of revenue at a 5.8% operating margin, growing 9.3%. CON earns 15.6%, CHE 12.9%, AVAH 10.9% and ADUS 9.8%. BrightSpring is the largest business in that group and the thinnest by margin at 2.4%. Scale is supposed to buy pricing power; here it has bought volume, and the profitability gap between BrightSpring and its smaller rivals has not closed.

Thin margins are where reimbursement risk becomes existential rather than annoying. Substantial revenue comes from Medicare and Medicaid, and the filing warns that changes to "Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services could materially adversely affect our business". Work the arithmetic: at 2.4%, a reimbursement change worth one percentage point of revenue removes about 40% of operating profit. There is no cushion in the structure of the business, only in its growth rate.

The referral base is not contracted either. In the company's own words, "Our referral sources are not, and cannot be, obligated to refer patients to us and may refer their patients to other providers." Every dollar of that 28% growth rests on relationships that can be redirected by a hospital system deciding to keep the pharmacy revenue.

What the price requires of all this is demanding. The market is paying roughly 52 times company-wide operating income, a multiple that sits at the very top of the peer distribution and well beyond its upper quartile, and that implies growth held at the company's self-funding ceiling for something like eleven years. Of comparable fast-growers, only about 14% sustained that kind of pace for a decade. The bet is not that the business is good. It is that a good business stays this good for eleven years without a reimbursement change, a vertically integrated competitor or a lost referral network interrupting it.

The balance sheet does not give much room for a mistake. Net borrowings run to 1.63 billion dollars, about 5.28 times operating profit, and operating income covers interest only about twice. Meanwhile the share count has grown roughly 7.8% a year over the last three years. The filing is explicit about the direction of travel: "You may be diluted by the future issuance of additional common stock in connection with our incentive plans, acquisitions or otherwise." Roughly 1.3 billion shares sit authorised but unissued. A roll-up that pays for acquisitions in stock, at a multiple this high, is at least buying cheaply with expensive currency. That works until the currency reprices.

Valuation

The market is paying roughly 52 times what BrightSpring earns before interest and tax. That is not a multiple you pay for a distribution business; it is a multiple you pay for a compounder, and it embeds a specific commitment: operating growth held at the company's self-funding ceiling for something like eleven years. The sensitivity around that is worth knowing. Each additional percentage point of growth pulls roughly two years off the requirement, and each point lost adds them back.

How rare is that commitment? The multiple sits at the very top of its peer distribution, well beyond the upper quartile. Looking at how such runs have actually ended, only about 14% of comparable fast-growers held that pace for anything like a decade. That is not a prediction of failure. It is the base rate a holder is betting against.

The methods used to triangulate a business like this split cleanly, and the split is informative. Only the forward-looking cash-flow methods reach today's price. The peer-multiple methods land well under it, with the price sitting about 85% above their central estimate, and the asset-value lens lands at roughly a quarter of the price. That is the signature of a durability premium: every static frame that values what exists today says the price is far past it, and the only frames that reach the price are the ones that credit years of future compounding.

Both of the static lenses are structurally handicapped here, which is worth saying plainly rather than treating their verdict as decisive. The earnings-power method capitalises a normalised operating profit with no growth at all, which for a business compounding revenue near 28% removes the entire thesis before it starts. The asset lens runs off book value, and this is a services roll-up whose value lives in payor contracts, pharmacy licences and referral relationships rather than in anything on the balance sheet. Their reads are real information about how little of the price is covered by demonstrated economics; they are not an independent verdict on the business.

Underneath, the composition is lopsided. Pharmacy Solutions is 89% of revenue and Provider Services 11%, and the 2.4% consolidated operating margin reflects the pharmacy mix, where drug acquisition cost dominates the revenue line. Against the comparison set that margin is the lowest: CON at 15.6%, CHE at 12.9%, AVAH at 10.9%, ADUS at 9.8%, ENSG at 8.5%, OPCH at 5.8%. The premium in the multiple is not being paid for current profitability. It is being paid for the belief that scale converts into it.

Solvency sets the outer edge of the downside. Gross borrowings of 2.52 billion dollars against 889 million of liquid assets leave net borrowings near 1.63 billion, about 5.28 times operating profit, with interest covered roughly twice and no cash burn. There was 475.0 million dollars of undrawn revolver capacity at the end of 2025. The share count is going up, not down, at about 7.8% a year over three years, so the per-share arithmetic gets no help from capital return. Coverage of two times is adequate for a business growing; it is thin for one that stops.

Catalysts

Second-quarter results arrive on 31 July 2026, before the market opens. The bar was set on 1 May, when first-quarter revenue came in at $3.61 billion and management raised full-year 2026 guidance to a revenue range of $14.73 billion to $15.23 billion and adjusted EBITDA of $795 million to $825 million. Given a raise cadence of nine guidance increases since 2024, the market has learned to expect another one, which is its own kind of risk: the price already contains the raise.

The portfolio question was settled earlier this year. The Community Living business went to Sevita in an all-cash deal worth $835 million, announced in January 2025 and finalised in March 2026 after the Federal Trade Commission required the buyer to divest 126 intermediate care facilities. The regulatory delay is the useful detail: antitrust review of post-acute care consolidation is now slow enough to matter to deal timing, and BrightSpring's own growth strategy runs on acquisitions.

The variable with the most leverage on the numbers is not a company event at all. It is reimbursement policy for Medicare Part D and Medicaid, which the company flags as a direct determinant of Pharmacy Solutions profitability. On a 2.4% operating margin, that policy file moves earnings more than any operational decision management makes this year.

Peer Cohorts (Per Segment, With Filing Citations)

Pharmacy Solutions (reported)

• OPCH (OPTION CARE HEALTH, INC.)
• FY2025 10-K: …and local levels places it in a strong position against existing and potential competitors. Intellectual Property Option Care Health and its subsidiaries own a variety of trademarks, licenses, and service marks, including but not limited to: "Option Care Health", "Option Care", "Critical Care Systems", "Clinical…
• FY2025 10-K: …infusion suites, and information technology infrastructure to support growth and create additional capacity in the future, as well as to pursue acquisitions and repurchases of Company shares. The Company's primary uses of cash and cash equivalents include supporting our ongoing business activities, internal…
• AVAH (Aveanna Healthcare Holdings Inc.)
• FY2025 10-K: …to patients including private duty nursing and therapy services, (ii) adult home health and hospice services (collectively "patient revenue"); and (iii) from the delivery of enteral nutrition and other products to patients ("product revenue"). The services provided by the Company have no fixed duration and can be…
• FY2025 10-K: …and support our future growth. We have invested significantly in our infrastructure and technology. Our frontline caregivers leverage our technology-enabled solutions, such as our remote care management tools that we deploy into patient homes to enhance data collection and the efficiency and quality of the caregiver…
• CHE (CHEMED CORPORATION)
• FY2025 10-K: …to its hospice operations. Similarly, VITAS obtains the majority of its medical supplies from a single vendor. A large majority of VITAS' pharmaceutical and medical supplies purchases are from these vendors. The pharmaceutical and medical supplies purchased by VITAS are available through many providers in the United…
• FY2025 10-K: …on stock options reduced our income tax expenses by $ 4.4 million, and $ 4.3 million for the years ended December 31, 2024 and 2023, respectively. During the third quarter of 2023, the Company recognized a tax benefit from realignment of its state and local corporate tax structure based on the location of operating…
• AHCO (AdaptHealth Corp.)
• FY2025 10-K: …respiratory failure. Diabetes Health The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes. Wellness at Home The Wellness at Home segment provides home medical equipment and services to patients in…
• FY2025 10-K: …Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. Diabetes Health The Diabetes Health segment provides…
• ENSG (ENSIGN GROUP, INC)
• FY2025 10-K: …and patient transportation to people in their homes or at long-term care facilities. To date, these businesses were not meaningful contributors to our operating results. GROWTH We have an established track record of successful acquisitions. Much of our historical growth can be attributed to implementing our expertise…
• FY2025 10-K: …ancillary services. We plan to continue to grow our revenue and earnings by: • continuing to grow our talent base and develop future leaders; • increasing the overall percentage or "mix" of higher acuity patients; • focusing on organic growth and operating efficiencies; • continuing to acquire additional operations…
• PACS (PACS Group, Inc.)
• FY2025 10-K: …care, assisted living, and independent living options in some of our communities. As of December 31, 2025, our portfolio consisted of 321 post-acute care, assisted living, and independent living facilities across 17 states serving over 31,700 patients daily. We believe our significant historical growth has been…
• FY2025 10-K: Our rapid growth in size and scale can be attributed to our deep bench of talented leaders. Our administrators in training provide us with leadership resources that we can use to quickly staff new facilities with qualified operators. Similarly, our RVPs enable us to scale within regions. We intend to invest heavily in…
• ADUS (Addus HomeCare Corp)
• FY2025 10-K: …restrictions on placing providers into preferred tiers. Trends toward clinical and pricing transparency may also impact our competitive position, ability to obtain and maintain favorable contract terms and consumer volumes. The current federal administration has signaled its commitment to advancing price transparency…
• FY2025 10-K: …growth while also growing through acquisitions, focusing on growth in the states in which we have a presence while adding clinical care services to our offerings. As of December 31, 2025, we provide all three levels of care, personal care, home health and hospice services, in Ohio, Tennessee, Illinois and New Mexico…
• CON (CONCENTRA GROUP HOLDINGS PARENT, INC.)
• FY2025 10-K: …strategic vision, and we continue to make advancements by introducing key technologies that focus on delivering an exceptional colleague and customer experience. One example is the Concentra HUB, our robust occupational health customer portal, which makes it easier and more convenient for employers, insurance…
• FY2025 10-K: …in our current business as well as expansion into adjacent, mission-aligned markets. Our experience in growing our presence and offerings to meet the evolving needs of our customers includes the completion of over 200 transactions since the Company's inception. As of December 31, 2025, our occupational health center…

Provider Services (reported)

• AVAH (Aveanna Healthcare Holdings Inc.)
• FY2025 10-K: …to patients including private duty nursing and therapy services, (ii) adult home health and hospice services (collectively "patient revenue"); and (iii) from the delivery of enteral nutrition and other products to patients ("product revenue"). The services provided by the Company have no fixed duration and can be…
• FY2025 10-K: …growth opportunity. In particular, we believe that the bundling of these services provides families with not only a more convenient "one stop shop" but also a more responsive, tailored service experience due to the ability of Aveanna nurses to manage patients' enteral shipments from the home. Today, we believe the…
• ADUS (Addus HomeCare Corp)
• FY2025 10-K: …oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping and transportation services. Many consumers need such services on a long-term basis to address chronic or acute conditions. Our personal care segment also includes staffing services, with clients including assisted…
• FY2025 10-K: …We generate net service revenues by providing our services directly to consumers and primarily on an hourly basis in our personal care segment, on a daily basis in our hospice segment and on an episodic basis in our home health segment. We receive payment for providing such services from our payor clients, including…
• ENSG (ENSIGN GROUP, INC)
• FY2025 10-K: …The payments are based on negotiated patient per diem rates or a negotiated fee schedule based on the type of service rendered. Reimbursement for Senior Living - Senior living facility revenue is primarily derived from private pay patients at rates we established, with the secondary source of revenue derived from…
• FY2025 10-K: $ 272,762 (1) Skilled services service revenue does not include intercompany service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in…
• PACS (PACS Group, Inc.)
• FY2025 10-K: …it adjusts these estimates, which would affect net service revenue in the period such variances become known. The Company maintains a refund liability for consideration collected related to revenue that is not probable that a significant revenue reversal will not occur. The Company expects to refund some or all of…
• FY2025 10-K: …care, assisted living, and independent living options in some of our communities. As of December 31, 2025, our portfolio consisted of 321 post-acute care, assisted living, and independent living facilities across 17 states serving over 31,700 patients daily. We believe our significant historical growth has been…
• ACHC (Acadia Healthcare Company, Inc.)
• FY2025 10-K: …services, the Company recognizes revenue equally over the patient stay on a daily basis. For outpatient services, the Company recognizes revenue equally over the number of treatments provided in a single episode of care. Typically, patients and third-party payors are billed within several days of the service being…
• FY2025 10-K: …market. Turning Point provides a full continuum of treatment services, including residential, partial hospitalization and intensive outpatient services. 41 Results of Operations The following table illustrates our consolidated results of operations for the respective periods shown (dollars in thousands): Year Ended…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.